SAT623 Everolimus For Treatment-refractory Prolactinomas

Disclosure: A.L. Lin: Grant Recipient; Self; Bristol-Myers Squibb. E.B. Geer: None. G. Page-Wilson: None. R.S. Magge: None. R.J. Young: Consulting Fee; Self; Olea Sphere, ICON plc. V. Tabar: None. Introduction: Treatment-refractory prolactinomas are life-limiting tumors without a standard of care tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Andrew L, Geer, Eliza Brevoort, Page-Wilson, Gabrielle, Magge, Rajiv S, Young, Robert J, Tabar, Viviane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Neuroendocrinology & Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553870/
http://dx.doi.org/10.1210/jendso/bvad114.1356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553870/
http://dx.doi.org/10.1210/jendso/bvad114.1356

Ejemplares similares